384
Views
1
CrossRef citations to date
0
Altmetric
Review

Emerging drugs for the treatment of sickle cell disease: a review of phase II/III trials

, &
Pages 211-224 | Received 08 Jun 2022, Accepted 21 Jul 2022, Published online: 01 Aug 2022

References

  • Piel FB, Steinberg MH, Rees DC. Sickle Cell Disease. N Engl J Med. 2017;376(16):1561–1573.
  • Gladwin MT, Vichinsky E. Pulmonary complications of sickle cell disease. N Engl J Med. 2008;359(21):2254–2265.
  • Matte A, Cappellini MD, Iolascon A, et al. Emerging drugs in randomized controlled trials for sickle cell disease: are we on the brink of a new era in research and treatment? Expert Opin Investig Drugs. 2020;29(1):23–31.
  • Howard J, Ataga KI, Brown RC, et al. Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematol. 2021;8(5):e323–e33.
  • Telen MJ. Curative vs targeted therapy for SCD: does it make more sense to address the root cause than target downstream events? Blood Adv. 2020;4(14):3457–3465.
  • Boye-Doe A, Brown E, Puri-Sharma C, et al. The grndad registry: contemporary natural history data and an analysis of Real-World patterns of use and limitations of disease modifying therapy in adults with SCD. Blood. 2020;136(Supplement 1):34–36.
  • Simpson S. Sickle cell disease: a new era. Lancet Haematol. 2019;6(8):e393–e4.
  • Grosse SD, Schechter MS, Kulkarni R, et al. Models of comprehensive multidisciplinary care for individuals in the United States with genetic disorders. Pediatrics. 2009;123(1):407–412.
  • Kanter J, Falcon C. Gene therapy for sickle cell disease: where we are now? Hematology. 2021;2021(1):174–180.
  • Quach D, Jiao B, Basu A, et al. A landscape analysis and discussion of value of gene therapies for sickle cell disease. Expert Rev Pharmacoecon Outcomes Res. 2022;1–21. DOI:10.1080/14737167.2022.2060823.
  • Payne AB, Mehal JM, Chapman C, et al. Trends in sickle cell Disease-Related mortality in the United States, 1979 to 2017. Ann Emerg Med. 2020;76(3s):S28–s36.
  • Vichinsky E, Hoppe CC, Ataga KI, et al. A phase 3 randomized trial of voxelotor in sickle cell disease. N Engl J Med. 2019;381(6):509–519.
  • Ashorobi D, Bhatt R. Bone marrow transplantation in sickle cell disease. 2019.
  • Singh PC, Ballas SK. Emerging drugs for sickle cell anemia. Expert Opin Emerg Drugs. 2015;20(1):47–61.
  • Yanni E, Grosse SD, Yang Q, et al. Trends in pediatric sickle cell disease-related mortality in the United States, 1983-2002. J Pediatr. 2009;154(4):541–545.
  • Chou ST, Alsawas M, Fasano RM, et al. American society of hematology 2020 guidelines for sickle cell disease: transfusion support. Blood Adv. 2020;4(2):327–355.
  • Uter S, An HH, Linder GE, et al. Measures to reduce red cell use in patients with sickle cell disease requiring red cell exchange during a blood shortage. Blood Adv. 2021;5(12):2586–2592.
  • Coates TD, Wood JC. How we manage iron overload in sickle cell patients. Br J Haematol. 2017;177(5):703–716.
  • Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia. N Engl J Med. 1995;332(20):1317–1322.
  • Steinberg MH, McCarthy WF, Castro O, et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. Am J Hematol. 2010;85(6):403–408.
  • Voskaridou E, Christoulas D, Bilalis A, et al. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood. 2010;115(12):2354–2363.
  • Hariri E, Mansour A, El Alam A, et al. Sickle cell nephropathy: an update on pathophysiology, diagnosis, and treatment. Int Urol Nephrol. 2018;50(6):1075–1083.
  • Ware RE, Davis BR, Schultz WH, et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial Doppler flow velocities in children with sickle cell anaemia—TCD with transfusions changing to hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet. 2016;387(10019):661–670.
  • McGann PT, Ware RE. Hydroxyurea therapy for sickle cell anemia. Expert Opin Drug Saf. 2015;14(11):1749–1758.
  • Ware RE. How I use hydroxyurea to treat young patients with sickle cell anemia. Blood. 2010;115(26):5300–5311.
  • Conran N, Torres L. cGMP modulation therapeutics for sickle cell disease. Exp Biol Med (Maywood). 2019;244(2):132–146.
  • Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. Jama. 2014;312(10):1033–1048.
  • Kotiah SD, Ballas SK. Investigational drugs in sickle cell anemia. Expert Opin Investig Drugs. 2009;18(12):1817–1828.
  • Walters MC, De Castro LM, Sullivan KM, et al. Indications and results of HLA-Identical sibling hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2016;22(2):207–211.
  • Frangoul H, Bobruff Y, Cappellini MD, et al. Safety and efficacy of CTX001 in patients with transfusion-dependent β-thalassemia and sickle cell disease: early results from the climb THAL-111 and climb SCD-121 studies of autologous CRISPR-CAS9-modified CD34+ hematopoietic stem and progenitor cells. Blood. 2020;136:3–4.
  • Ribeil J-A, Hacein-Bey-Abina S, Payen E, et al. Gene therapy in a patient with sickle cell disease. N Engl J Med. 2017;376(9):848–855.
  • Jones RJ, DeBaun MR. Leukemia after gene therapy for sickle cell disease: insertional mutagenesis, busulfan, both, or neither. Blood. 2021;138(11):942–947.
  • Huo J, Xiao H, Garg M, et al. The economic burden of sickle cell disease in the United States. Value Health. 2018;21:S108.
  • Carden MA, Little J. Emerging disease-modifying therapies for sickle cell disease. Haematologica. 2019;104(9):1710–1719.
  • Ataga KI, Desai PC. Advances in new drug therapies for the management of sickle cell disease. Expert Opin Orphan Drugs. 2018;6(5):329–343.
  • Telen MJ, Malik P, Vercellotti GM. Therapeutic strategies for sickle cell disease: towards a multi-agent approach. Nat Rev Drug Discov. 2019;18(2):139–158.
  • Ataga KI, Kutlar A, Kanter J, et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med. 2017;376(5):429–439.
  • Tampaki A, Gavriilaki E, Varelas C, et al. Complement in sickle cell disease and targeted therapy: i know one thing, that I know nothing. Blood Rev. 2021;48:100805.
  • Casella JF, Barton BA, Kanter J, et al. Effect of Poloxamer 188 vs placebo on painful Vaso-Occlusive episodes in children and adults with sickle cell disease: a randomized clinical trial. Jama. 2021;325(15):1513–1523.
  • Vona R, Sposi NM, Mattia L, et al. Sickle cell disease: role of oxidative stress and antioxidant therapy. Antioxidants. 2021;10(2):296.
  • Mack AK, Kato GJ. Sickle cell disease and nitric oxide: a paradigm shift? Int J Biochem Cell Biol. 2006;38(8):1237–1243.
  • Kaddam L, Fadl-Elmula I, Eisawi OA, et al. Gum Arabic as novel anti-oxidant agent in sickle cell anemia, phase II trial. BMC Hematol. 2017;17(1):1–6.
  • Eaton WA, Hofrichter J. Sickle cell hemoglobin polymerization. Adv Protein Chem. 1990;40:63–279.
  • Esrick EB, McConkey M, Lin K, et al. Inactivation of HDAC 1 or HDAC 2 induces gamma globin expression without altering cell cycle or proliferation. Am J Hematol. 2015;90(7):624–628.
  • Steinberg MH. Fetal hemoglobin in sickle cell anemia. Blood. 2020;136(21):2392–2400.
  • Vissa M, Vichinsky E. Voxelotor for the treatment of sickle cell disease. Expert Rev Hematol. 2021;14(3):253–262.
  • Vichinsky E, Gordeuk VR, Telfer P, et al. Higher hemoglobin levels achieved with voxelotor are associated with lower vaso-occlusive crisis incidence: 72-week analysis from the HOPE study. Blood. 2020;136:31–32.
  • Shah N, Lipato T, and Alvarez O, et al. Real-world effectiveness of voxelotor for treating sickle cell disease in the US: a large claims data analysis. Expert Rev Hematol. 2022;15(2):167–173.
  • Brown RCC, Redfern A, Lisbon E, et al. GBT021601, a next generation HbS polymerization inhibitor: results of safety, tolerability, pharmacokinetics and pharmacodynamics in adults living with sickle cell disease and healthy volunteers. Blood. 2021;138:3099.
  • Rab MA, Bos J, van Oirschot BA, et al. Decreased activity and stability of pyruvate kinase in sickle cell disease: a novel target for mitapivat therapy. Blood J Am Soc Hematol. 2021;137(21):2997–3001.
  • Schroeder P, Fulzele K, Forsyth S, et al. Etavopivat, a pyruvate kinase activator in red blood cells, for the treatment of sickle cell disease. J Pharmacol Exp Ther. 2022;380(3):210–219.
  • Xu JZ, Conrey A, Frey I, et al. Mitapivat (AG-348) demonstrates safety, tolerability, and improvements in anemia, hemolysis, oxygen affinity, and hemoglobin S polymerization kinetics in adults with sickle cell disease: a phase 1 dose escalation study. Blood. 2021;138:10.
  • Ikuta T, Ausenda S, Cappellini MD. Mechanism for fetal globin gene expression: role of the soluble guanylate cyclase–cGMP-dependent protein kinase pathway. Proc Nat Acad Sci. 2001;98(4):1847–1852.
  • Head CA, Swerdlow P, McDade WA, et al. Beneficial effects of nitric oxide breathing in adult patients with sickle cell crisis. Am J Hematol. 2010;85(10):800–802.
  • Weiner DL, Hibberd PL, Betit P, et al. Preliminary assessment of inhaled nitric oxide for acute vaso-occlusive crisis in pediatric patients with sickle cell disease. Jama. 2003;289(9):1136–1142.
  • Gladwin MT, Kato GJ, Weiner D, et al. Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis: a randomized controlled trial. Jama. 2011;305(9):893–902.
  • Morris CR, Kuypers FA, Lavrisha L, et al. A randomized, placebo-controlled trial of arginine therapy for the treatment of children with sickle cell disease hospitalized with vaso-occlusive pain episodes. Haematologica. 2013;98(9):1375.
  • Miyashiro J, Pant A, Tchernychev B, et al. The effect of the soluble guanylyl cyclase stimulator olinciguat on ƴ-globin gene induction in K562 cells. Blood. 2018;132:1078.
  • Potoka KP, Gladwin MT. Vasculopathy and pulmonary hypertension in sickle cell disease. Am J Physiol Lung Cell Mol Physiol. 2015;308(4):L314–L24.
  • Potoka KP, Wood KC, Baust JJ, et al. Nitric oxide–independent soluble guanylate cyclase activation improves vascular function and cardiac remodeling in sickle cell disease. Am J Respir Cell Mol Biol. 2018;58(5):636–647.
  • Andemariam B, Mant T, Eleftheriou P, et al. Treatment with IMR-687, a highly selective PDE9 inhibitor, increases HbF and reduces VOCs in adults with sickle cell disease in a Long-Term, phase 2a, Open-Label extension study. Blood. 2021;138:2046.
  • Manwani D. P-selectin and sickle cell disease: a balancing act. Blood J Am Soc Hematol. 2021;137(19):2573–2574.
  • Telen MJ, Wun T, McCavit TL, et al. Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use. Blood. 2015;125(17):2656–2664.
  • Dampier CD, Telen MJ, Wun T, et al. Early initiation of treatment with rivipansel for acute vaso-occlusive crisis in sickle cell disease (SCD) achieves earlier discontinuation of IV opioids and shorter hospital stay: reset clinical trial analysis. Blood. 2020;136:18–19.
  • Biemond BJ, Tombak A, Kilinc Y, et al. Sevuparin for the treatment of acute pain crisis in patients with sickle cell disease: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Haematol. 2021;8(5):e334–e43.
  • Han J, Saraf SL, Gordeuk VR. Systematic review of crizanlizumab: a new parenteral option to reduce Vaso-occlusive pain crises in patients with sickle cell disease. Pharmacotherapy. 2020;40(6):535–543.
  • Mayer C, Cooper DS, Redfern A, et al. Preliminary results of a phase 1 study in healthy subjects administered inclacumab, a fully human IgG4 Anti-P-Selectin monoclonal antibody in development for treatment of sickle cell disease. Blood. 2021;138:977.
  • Telen MJ. Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease. Blood J Am Soc Hematol. 2016;127(7):810–819.
  • Orringer EP, Casella JF, Ataga KI, et al. Purified poloxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease: a randomized controlled trial. Jama. 2001;286(17):2099–2106.
  • Qari MH, Aljaouni SK, Alardawi MS, et al. Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial. Thromb Haemost. 2007;98(2):392–396.
  • Heeney MM, Hoppe CC, Abboud MR, et al. A multinational trial of prasugrel for sickle cell vaso-occlusive events. N Engl J Med. 2016;374(7):625–635.
  • Kanter J, Abboud MR, Kaya B, et al. Ticagrelor does not impact patient‐reported pain in young adults with sickle cell disease: a multicentre, randomised phase II b study. Br J Haematol. 2019;184(2):269–278.
  • Wun T, Soulieres D, Frelinger AL, et al. A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease. J Hematol Oncol. 2013;6(1):1–10.
  • Quinn CT. l-Glutamine for sickle cell anemia: more questions than answers. Blood J Am Soc Hematol. 2018;132(7):689–693.
  • Niihara Y, Miller ST, Kanter J, et al. A phase 3 trial of l-glutamine in sickle cell disease. N Engl J Med. 2018;379(3):226–235.
  • Niihara Y, Macan H, Eckman J, et al. L-Glutamine therapy reduces hospitalization for sickle cell anemia and sickle β°-thalassemia patients at six months–a phase II randomized trial. Clin Pharmacol Biopharm. 2014;3(116):2.
  • Heyland D, Muscedere J, Wischmeyer PE, et al. A randomized trial of glutamine and antioxidants in critically ill patients. N Engl J Med. 2013;368(16):1489–1497.
  • Nur E, Brandjes DP, Teerlink T, et al. N-acetylcysteine reduces oxidative stress in sickle cell patients. Ann Hematol. 2012;91(7):1097–1105.
  • Sins JW, Fijnvandraat K, Rijneveld AW, et al. N-acetylcysteine in patients with sickle cell disease: a randomized controlled trial. Blood. 2016;128(22):123.
  • Lal A, Suh J, Atamna W, et al. Anti-Oxidant treatment with α-Lipoic acid and Acetyl L-Carnitine in hemoglobinopathies. Blood. 2007;110(11):3799.
  • Bao B, Prasad AS, Beck FW, et al. Zinc supplementation decreases oxidative stress, incidence of infection, and generation of inflammatory cytokines in sickle cell disease patients. Transl Res. 2008;152(2):67–80.
  • Rees DC, Kilinc Y, Unal S, et al. A randomized, placebo-controlled, double-blind trial of canakinumab in children and young adults with sickle cell anemia. Blood J Am Soc Hematol. 2022;139(17):2642–2652.
  • Glassberg J, Minnitti C, Cromwell C, et al. Inhaled steroids reduce pain and sVCAM levels in individuals with sickle cell disease: a triple‐blind, randomized trial. Am J Hematol. 2017;92(7):622–631.
  • Lim SH, Dutta D, Moore J. Rifaximin for sickle cell disease. Am J Hematol. 2019;94(12):E325–E8.
  • Lim SH, Morris A, Li K, et al. Intestinal microbiome analysis revealed dysbiosis in sickle cell disease. Am J Hematol. 2018;93(4):E91–E3.
  • Bartolucci P, Ataga K, Callaghan M, et al. P119: trial in progress: the randomized, double-blind, placebo-controlled phase 1B CROSSWALK-A trial evaluating the safety of Crovalimab for the management of acute uncomplicated vaso-occlusive episodes (VOES) in patients (PTS) with sickle cell disease (SCD). HemaSphere. 2022;6(Suppl):27.
  • Thomas AM, Gerogianni A, McAdam MB, et al. Complement component C5 and TLR molecule CD14 mediate heme-induced thromboinflammation in human blood. J Immunol. 2019;203(6):1571–1578.
  • Darbari DS, Wang Z, Kwak M, et al. Severe painful vaso-occlusive crises and mortality in a contemporary adult sickle cell anemia cohort study. PloS one. 2013;8(11):e79923.
  • Shah N, Bhor M, Xie L, et al. Evaluation of vaso-occlusive crises in United States sickle cell disease patients: a retrospective claims-based study. J Health Econ Outcomes Res. 2019;6(3):106.
  • Glaros AK, Razvi R, Shah N, et al. Voxelotor: alteration of sickle cell disease pathophysiology by a first-in-class polymerization inhibitor. Ther Adv Hematol. 2021;12:20406207211001136.
  • Machado RF, Barst RJ, Yovetich NA, et al. Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. Blood J Am Soc Hematol. 2011;118(4):855–864.
  • Lee LH, Whisenton LH, Benger J, et al. A community-centered approach to sickle cell disease and clinical trial participation: an evaluation of perceptions, facilitators, and barriers. Blood Adv. 2021;5(23):5323–5331.
  • Tshilolo L, Tomlinson G, Williams TN, et al. Hydroxyurea for children with sickle cell anemia in sub-Saharan Africa. N Engl J Med. 2019;380(2):121–131.
  • Pecker LH, Lanzkron S. Sickle cell disease. Ann Intern Med. 2021;174(1):ITC1–ITC16.
  • Gualandro SFM, Fonseca GH, Yokomizo IK, et al. Cohort study of adult patients with haemoglobin SC disease: clinical characteristics and predictors of mortality. Br J Haematol. 2015;171(4):631–637.
  • Luchtman-Jones L, Pressel S, Hilliard L, et al. Effects of hydroxyurea treatment for patients with hemoglobin SC disease. Am J Hematol. 2016;91(2):238–242.
  • Pecker LH, Schaefer BA, Luchtman‐Jones L. Knowledge insufficient: the management of haemoglobin SC disease. Br J Haematol. 2017;176(4):515–526.
  • Mnika K, Pule GD, Dandara C, et al. An expert review of pharmacogenomics of sickle cell disease therapeutics: not yet ready for global precision medicine. OMICS. 2016;20(10):565–574.
  • Investigators OPSPiSCAT. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med. 2005;353(26):2769–2778.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.